Varlitinib is under clinical development by Aslan Pharmaceuticals and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Varlitinib’s likelihood of approval (LoA) and phase transition for Gastroesophageal (GE) Junction Carcinomas took place on 16 Feb 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Varlitinib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Varlitinib overview

ASLAN-001 (varlitinib) is under development for the treatment of solid tumors such as breast cancer (Her2-positive), ovarian cancer, gastro-oesophageal junction, colorectal cancer, cholangiocarcinoma, gastric cancer (second-line therapy), gallbladder cancer, metastatic hepatocellular carcinoma and carcinoma of ampulla of vater. The drug candidate is administered through the oral route. It targets HER1, HER2, HER3 and HER4 receptors.

It was also under development for pancreatic cancer and metastatic gastric cancer, gastro-oesophageal junction cancer (second-line therapy) and metastatic biliary tract cancer (first line therapy).

Aslan Pharmaceuticals overview

Aslan Pharmaceuticals is a clinical-stage biotechnology company that develops novel therapeutics for various oncology diseases. The company’s pipeline products include Varlitinib, ASLAN003, ASLAN004 and ASLAN002. Its Varlitinib is a pan-HER inhibitor used for the treatment of biliary tract cancer, gastric cancer, breast cancer and colorectal cancer. Aslan Pharmaceuticals’ ASLAN003 is a DHODH inhibitor used for the treatment of acute myeloid leukemia; ASLAN004 is an IL-4/IL-13 receptor inhibitor used for the treatment of asthma and atopic dermatitis; and ASLAN002 is a RON/MET inhibitor used for the treatment of solid tumors. The company conducts regional clinical development programs across Asia. It operates its offices in Singapore, Taiwan and China. Aslan Pharmaceuticals is headquartered in Singapore.

Quick View Varlitinib LOA Data

Report Segments
  • Innovator
Drug Name
  • Varlitinib
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.